Laurus Labs Stock Hits New Peak

On Monday, shares of leading pharmaceutical company Laurus Labs surged sharply in the stock market. Despite the broader market witnessing a decline, Laurus Labs, along with several other pharma stocks, delivered a strong performance. The company's shares touched a fresh 52-week high of Rs. 1,530. The stock remained in positive territory throughout Monday's trading session and ended the day with substantial gains. After hitting an intraday high of Rs. 1,530, the shares closed at Rs. 1,503, up Rs. 52 at the end of the session. The company's share price has been rising steadily over the past several months and has now reached a new high. Expectations are that the company's margins will improve further as it sharpens its focus on its Contract Development and Manufacturing Organization (CDMO) business.

In addition, the company plans to focus on its non-pharma businesses, including Animal Health and Crop Science. Several brokerage firms remain highly bullish on Laurus Labs' CDMO business. Over the next two years, Laurus Labs plans to invest as much as Rs. 3,000 crore. The investment will be used to expand manufacturing capacity and set up new production units. Since the stock closed above Rs. 1,500 on Monday, market expectations are that the momentum in Laurus Labs shares could continue for some more time. Meanwhile, the BSE Sensex witnessed significant volatility during Monday's trading session before ending 372 points lower at 76,728.